logo

Amicus Therapeutics Inc. (FOLD)



Trade FOLD now with
  Date
  Headline
10/10/2019 7:38:02 AM Amicus Expects About $48 Mln In Galafold Revenue For Q3
8/2/2019 7:13:24 AM Amicus Therapeutics Receives Marketing Authorization For Galafold For Fabry Disease In Argentina
7/2/2019 7:37:16 AM Amicus Enters Strategic Manufacturing Agreement With Paragon Gene Therapy
7/1/2019 7:08:04 AM Amicus Therapeutic Enters Strategic Manufacturing Collaboration With Thermo Fisher Scientific
5/29/2019 6:34:25 AM Amicus Therapeutics And The University Of Pennsylvania Announce Expansion Of Gene Therapy Collaboration
1/7/2019 7:14:43 AM Amicus Therapeutics Reports Full-Year 2018 Galafold Revenue Of $91 Mln
1/3/2019 7:05:44 AM Amicus Therapeutics Begins Phase 1/2 Study Of Gene Therapy For CLN3 Batten Disease
12/20/2018 7:04:40 AM Amicus Therapeutics Says First Patient Dosed In Phase 3 PROPEL Pivotal Study Of AT-GAA In Patients With Pompe Disease
11/5/2018 7:11:35 AM Amicus Therapeutics Q3 Net Loss $159.2 Mln Or $0.84/Shr Vs Net Loss $111.7 Mln Or $0.69/Shr Last Year
10/8/2018 7:04:53 AM Amicus Enters R&D Collaboration With University Of Pennsylvania To Develop AAV Gene Therapies
10/5/2018 7:03:22 AM Amicus Therapeutics Announces Positive 18-Month Data In Pompe Disease Phase 1/2 Study
9/20/2018 6:03:03 AM Amicus Therapeutics Acquires Gene Therapy Portfolio Of Ten Clinical And Pre-Clinical Stage AAV Programs
9/11/2018 7:05:06 AM Amicus Therapeutics Appoints Lynn Bleil To Its Board
8/7/2018 7:19:06 AM Amicus Therapeutics Q2 Net Loss $61.8 Mln Or $0.33/Shr Vs Loss Of $48.1 Mln Or $0.34/Shr Last Year
6/8/2018 7:00:35 AM Amicus Therapeutics Appoints President And COO Bradley Campbell To Board
5/30/2018 12:06:19 AM Amicus Therapeutics Launches Galafold For Fabry Disease In Japan
5/8/2018 7:12:49 AM Amicus Therapeutics Q1 Net Loss $49.9 Mln Or $0.28/Shr Vs Loss Of $55.0 Mln Or $0.39/Shr Last Year
  
 
>